New
Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
HELX ETF · Franklin Genomic Advancements ETF
The HELX Exchange Traded Fund (ETF) is provided by Franklin Templeton. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.-9.33%
Last price
$32.37
1M perf.
-8.23%
1M flows
N/A
AuM
€18M
E/R
0.5%
Rating
Not rated
ESG Consensus®
HELX
$32.37
Performance & flows
Segment for quartile rank
December 19, 2025 → March 19, 2026
Create a free account to view the flows graph
HELX
$32.34
-12.00%
BioTech & Genomics
-8.14%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -8.23%  | -12.00%  | +13.51% | +9.55%  | -25.83% | -6.43% | -10.88% | -10.88% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/19/2026
$32.34
1D NAV change
+0.45%
Dividend policy
No. of holdings
60
Inception date
2/25/2020
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Fund
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The Fund seeks capital appreciation by investing in innovative companies related to genomic-based technologies designed to enhance the quality of life.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
CURE
1M perf.
-6.33%
E/R
0.35%
FMED
1M perf.
-7.22%
E/R
0.5%
EKG
1M perf.
-6.81%
E/R
0.65%
DOCG
1M perf.
-9.59%
E/R
0.49%
HTEC
1M perf.
-9.17%
E/R
0.8%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -12.00% | +13.51% | +9.55% | -25.83% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
87.28%
Republic of Korea
4.23%
United Kingdom
3.35%
Netherlands
2.41%
Germany
1.02%
Other
1.71%
Sectors
Health Care
89.14%
Materials
2.41%
Unavailable
7.78%
Other
0.68%
Diversification
Total weight of top 15 holdings out of 60
Top 15 holdings
Data as of February 28, 2026
NATERA
GUARDANT HEALTH INC
KRYSTAL BIOTECH INC
INSMED
BRIDGEBIO PHARMA
UTD THERAPEUT
SAMSUNG BIOLOGICS CO LTD
ADAPTIVE BIOTECHNOLOGIES
Create a free account to view top holdings
ASTRAZENECA
ALNYLAM PHARMACEUTICALS
LIGAND PHARMACEUTICALS
VERTEX PHARMACEUTICALS
LILLY
MEDPACE HOLDINGS INC
REGENERON PHARMACEUTICALS
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Franklin Templeton
Franklin Templeton ID Card
Number of funds
149
Total AuM
€46.84B
Expense ratio range
0.03% - 0.99%
Average expense ratio
0.2745%
Top 5 funds by Franklin Templeton
| AuM | ||
|---|---|---|
LVHI | Franklin International Low Volatility High Dividend Index ETF | €3.95B |
FLXK | Franklin FTSE Korea UCITS ETF | €2.79B |
FLJP | Franklin FTSE Japan ETF | €2.63B |
FLCB | Franklin U.S. Core Bond ETF | €2.5B |
FLIN | Franklin FTSE India ETF | €2.29B |
Frequently asked questions about HELX
What does Franklin Genomic Advancements ETF, HELX, invest in?
HELX is a Active ETF. This ETF provides exposure to Other Global Equities.
What is the Total Expense ratio (TER) of HELX?
HELX carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
When was HELX launched?
HELX was introduced to the market on February 25, 2020. It trades on United States
Who is the ETF issuer of HELX?
Franklin Genomic Advancements ETF, HELX, is provided by Franklin Templeton. Learn more about Franklin Templeton here.
What is the current assets under management (AUM) of HELX?
HELX oversees €18M in assets as of March 19, 2026.
How has HELX performed lately?
Based on data from March 19, 2026, HELX returned -8.23% over the past month, -12.00% over the last three months and -10.88% year-to-date.
What are the latest inflows or outflows for HELX?
As of March 19, 2026, HELX recorded net flows of +€1.6M year-to-date.
Does HELX distribute dividends?
HELX follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of HELX?
As of February 28, 2026, HELX has significant geographic allocations in USA, Republic of Korea and United Kingdom.
In which sector or theme does HELX invest in?
As of February 28, 2026, HELX focuses largely on Health Care and Materials.
How many securities does HELX hold and how diversified is it?
As of February 28, 2026, HELX holds 60 positions in its portfolio, with 58.64% of assets concentrated in its top 15 holdings.
What are the main positions in HELX?
As of February 28, 2026, HELX top three holdings include NATERA, GUARDANT HEALTH INC and KRYSTAL BIOTECH INC.
What is the base currency of HELX?
The base currency of HELX is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
